NARA Discovery
Article Details
← Back to Search Results
Journal Article

Validation and performance assessment of a commercial anti-peroxidasin antibody

Isabel Brandão; Roberto Silva; Bárbara Gomes; Jorge R. Almeida; João Paulo Oliveira; Inês S. Alencastre
Histochemistry and Cell Biology · Vol. 164, Issue 1 · 2026

Abstract

Peroxidasin (PXDN) is a multi-domain heme peroxidase that catalyzes sulfilimine cross-links in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunohistochemistry and immunocytochemistry applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and in a primary kidney fibroblast line under PXDN silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.

Bibliographic Information

JournalHistochemistry and Cell Biology
PublisherSpringer
Publication Date2026-01-21
Publication Year2026
Volume164
Issue1
Document TypeJournal Article
eISSN1432-119X
DOI10.1007/s00418-025-02453-7

Access Information

NARA Access Coverage1958-01-01~Current
Journal Homepagehttps://www.springer.com/journal/418
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.